Rituximab Articles
Genentech gets subpoena on Rituxan
11 October 2004
Roche's MabThera OKed in UK for first-line use in NHL
20 September 2004
Israel: complaints over funds' drug access
23 August 2004
Biogen Idec closes 2nd-qtr above expectations
9 August 2004
Genentech's 2nd-qtr sales rocket 42%
19 July 2004
Corixa files sBLA in USA for Bexxar
12 July 2004
MabThera on track for first-line use in NHL
5 July 2004
Stock Commentary - Europe
28 June 2004
Stock Commentary - New York
14 June 2004
Biogen Idec's 1st-qtr revenues rise 24%
10 May 2004
Roche 1st-qtr beats expectations
26 April 2004
Stock Commentary - Europe
19 April 2004
Genentech's sales up 28% for 1st-qtr 2004
19 April 2004
Pegasys still driving Roche's growth
29 March 2004
Chiron to discontinue tezacitabine program
29 March 2004
Chugai's 1st 9-mth earnings beat forecasts
8 March 2004
Merger costs Biogen Idec a $991M loss
8 March 2004
Roche beats forecasts with sales up 19%
9 February 2004
Tokyo pharma stocks - week to Jan 26
2 February 2004
Schering AG's Zevalin cleared by EC
26 January 2004
MabThera EU filing for first-line indolent NHL
26 January 2004
New data for Rituxan/ MabThera at ASH
15 December 2003
GPC Biotech aiming to build broad oncology pipeline
24 November 2003
Rituximab meets goal in NHL trial
24 November 2003
Stock Commentary - New York
10 November 2003
Roche beats forecasts with pharma sales up 13% in first 9 months
27 October 2003
Stock Commentary - New York
20 October 2003
Rituxan drives IDEC upwards in 3rd quarter
20 October 2003
Schering AG's Zevalin gets positive opinion
6 October 2003
UK NICE recommends Roche's MabThera
29 September 2003
Corixa/GSK's Bexxar launched in the USA
11 August 2003
Roche posts sharp fall in 1st-half profit
28 July 2003
Genentech swings to profit as sales soar
14 July 2003
MabThera increases survival against NHL
9 June 2003
Stock Commentary - New York
2 June 2003
Rituxan deal drives IDEC revenues higher
28 April 2003
Strong growth for Genentech in 1st-qtr
21 April 2003
Novuspharma losses rocket in 2002
10 March 2003
Stock Commentary - week to Jan 20 - New York
27 January 2003
IDEC EPS out-performs in fourth qtr
27 January 2003
Genentech
20 January 2003
Roche profits hit by weak foreign currency
19 August 2002
Stock Commentary - New York
22 July 2002
IDEC 2nd-qtr sales increase 43%
22 July 2002
Genentech posts $214M loss in 2nd qtr
22 July 2002
IDEC forecasts 2nd-qtr EPS at $0.20
15 July 2002
Stock Commentary - New York
15 July 2002
Rituxan effective in treating rheumatoid arthritis
24 June 2002
Royalty Pharma cancel Swiss IPO
24 June 2002
Somatropin OK for GH deficiency: UK NICE
3 June 2002
1st qtr 2002 "a let down for biotech"
6 May 2002
IDEC results driven by Rituxan
29 April 2002
Genentech 1st-qtr earnings leap
22 April 2002
40% growth for IDEC/Genentech
15 April 2002
IDEC launches Zevalin in USA for NHL
1 April 2002
Dynavax to test ISS drug plus Rituxan in NHL
1 April 2002
Sales of non-Hodgkin's lymphoma drugs to boom
25 March 2002
UK NICE's proposed guidance timetable
25 March 2002
Genta starts trial of Genasense plus Rituxan
25 February 2002
Tokyo pharma stocks - week to February 18
25 February 2002
Stock Commentary - New York
25 February 2002
Genentech full-year 2001 revenues increase 28%
28 January 2002
IDEC/Genentech collaboration on Rituxan achieves $779M sales
28 January 2002
Mabthera/CHOP increase chance of NHL cure
13 December 2001
Amgen's epratuzumab in combo regimen for NHL
12 December 2001
Stock Commentary - New York
25 October 2001
Genentech third-qtr revenues jump 24%
16 October 2001
IDEC Pharma says 3rd qtr sales of Rituxan reach $205 million
15 October 2001
Genentech third-qtr revenues jump 24%
12 October 2001
Roche's MabThera launched in Japan
14 September 2001
IDEC's Zevalin set for US approval for NHL
12 September 2001
Genentech earnings set to grow 25%
11 September 2001
FDA's ODAC to review Gliadel, Zevalin
4 September 2001
Analyst initiates coverage of PDL and IDEC
31 August 2001
FDA committee to review IDEC's Zevalin
23 July 2001
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
